0.06 | 1.36%
| Price and Volume | |
|---|---|
| Recent Price | 5.93 |
| 52 Week High | 8.07 |
| 52 Week Low | 3.46 |
| Avg. Daily Vol. (Mil) | 0.27 |
| Beta (3 year) | 0.77 |
| Share Related Items | |
| Mkt Cap (Mil) | 211.83 |
| Shares Out (Mil) | 35.72 |
| Float (Mil) | 21.27 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 8.10 |
| Current Ratio | 8.40 |
| LT Debt/ Equity | 0.00 |
| Total Debt / Equity | 0.00 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 3.96 |
| Price/Book | 3.08 |
| Price/Cash Flow | -9.90 |
| Per Share Data | |
| Earnings | -0.71 |
| Sales | 1.50 |
| Book Value | 1.93 |
| Cash Flow | -0.60 |
| Business Summary | |
|---|---|
| XenoPort, Inc. is a biopharmaceutical is focused on developing and commercializing a portfolio of internally discovered product candidates that utilize the body's natural nutrient transport mechanisms to improve the therapeutic benefits. | |
| General Information | |
| 3410 Central Expressway
Santa Clara, CA 95051 |
|
| www.xenoport.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 112 | |
| CEO: Dr. Ronald W. Barrett,Ph | |
| Short Interest | |
| Current Month (Mil) | 2.41 |
| Previous Month (Mil) | 2.31 |
| Short Interest Ratio (Days) | 8.30 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -27.00 |
| Return on Investments | -36.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | -47.40 |
| Profit Margin | -47.40 |
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note |
|
|---|---|---|---|---|
| 12,419.86 | 1,313.32 | 2,837.36 | 16.25 |
Oil *
103.00
|
|
DOWN
160.83 |
DOWN
19.10 |
DOWN
33.63 |
DOWN
1.06 |
10 Yr
1.62%
SPDR Gold
151.91
|
|
-1.28%
|
-1.43%
|
-1.17%
|
-6.12%
|
Data delayed 20 minutes |
Connect with TheStreet